CVS Health CVS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
CVS Health (CVS) Core Market Data and Business Metrics
Latest Closing Price
$68.07Price-Earnings Ratio
17.23Total Outstanding Shares
1.26 Billion SharesDividend
$0.67 Per Share QuarterlySIC Description
Retail-drug Stores And Proprietary StoresPrimary Exchange
New York Stock ExchangeHeadquarters
One Cvs Dr., Woonsocket, RI, 02895
Historical Stock Splits
If you bought 1 share of CVS before June 7, 2005, you'd have 2 shares today.
Execution Date | Split Amount |
---|---|
June 7, 2005 | 2-for-1 |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
---|---|---|---|
7,965,639 Shares | 2.5 | 3/14/2025 | 19,880,048 Shares |
9,582,082 Shares | 2.15 | 2/28/2025 | 20,554,799 Shares |
13,555,203 Shares | 1.74 | 2/14/2025 | 23,600,102 Shares |
12,163,107 Shares | 1.76 | 1/31/2025 | 21,351,591 Shares |
14,877,388 Shares | 1.14 | 1/15/2025 | 16,990,142 Shares |
17,450,510 Shares | 1.04 | 12/31/2024 | 18,097,574 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-8.31 Billion |
Net Cash Flow | $-6.24 Billion |
Net Cash Flow, Continuing | $-6.24 Billion |
Net Cash Flow From Investing Activities | $-8.31 Billion |
Net Cash Flow From Financing Activities | $-2.54 Billion |
Net Cash Flow From Operating Activities | $4.61 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Revenues | $368.91 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $5.02 Billion |
Benefits Costs and Expenses | $362.19 Billion |
Net Income/Loss Attributable To Parent | $5.02 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Basic Earnings Per Share | $3.95 |
Comprehensive Income
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Comprehensive Income/Loss | $1.21 Billion |
Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-6 Million |
Comprehensive Income/Loss Attributable To Parent | $6.23 Billion |
Comprehensive Income/Loss | $6.22 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Liabilities | $92.69 Billion |
Equity Attributable To Noncontrolling Interest | $162 Million |
Current Assets | $67.34 Billion |
Inventory | $17.65 Billion |
Liabilities | $177.32 Billion |
Assets | $252.43 Billion |
Historical Dividends
Current dividend: $0.67 Per Share Quarterly
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
Mar 20, 2025 | May 1, 2025 | Apr 22, 2025 | $0.665 | Quarterly |
Jan 3, 2025 | Feb 3, 2025 | Jan 23, 2025 | $0.665 | Quarterly |
Sep 19, 2024 | Nov 1, 2024 | Oct 21, 2024 | $0.665 | Quarterly |
Jul 8, 2024 | Aug 1, 2024 | Jul 22, 2024 | $0.665 | Quarterly |
Mar 21, 2024 | May 1, 2024 | Apr 22, 2024 | $0.665 | Quarterly |
Dec 5, 2023 | Feb 1, 2024 | Jan 22, 2024 | $0.665 | Quarterly |
CVS Articles From Financhle
Recent analysis, market insights, and in-depth coverage of CVS from analysts at Financhle
- CVS Health's Q4 FY2024 Earnings Report Unpacked: Triumphs, Trials, and Future ProspectsAnalyze CVS Health's Q4 FY2024 earnings through a lens of strategic nuance and market acumen. Click to understand the interplay of growth, challenges, and forward-thinking in one of healthcare's leading orchestrators.February 12, 2025